First Western Ship Transits Strait of Hormuz Since Iran War Began 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Britain Courts Anthropic Amid US Defense Department Dispute 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple Turns 50: From Garage Startup to AI Crossroads 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SAN CARLOS, Calif., July 25, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its second quarter 2017 financial and operating results after the close of the U.S. financial markets on Tuesday, August 1, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 5:00 p.m. ET.
In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 47307932. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: http://edge.media-server.com/m/p/so22t2sr.
A replay of the call will be available one hour after the end of the call on August 1, 2017 until 8:00 p.m. ET on August 31, 2017. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 47307932. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with refractory metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and cervical cancer. For more information, please visit http://www.iovance.com.
Investor Contact: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 [email protected] Media Contact: Media Relations Contact: Evan Smith/Kotaro Yoshida FTI Consulting 212-850-5622/212-850-5690 [email protected] [email protected]
